<DOC>
	<DOCNO>NCT01096745</DOCNO>
	<brief_summary>The purpose study compare efficacy gemcitabine/cisplatin S-1/cisplatin first-line treatment advance biliary tract cancer .</brief_summary>
	<brief_title>Randomized Trial Gemcitabine/Cisplatin Versus S-1/Cisplatin Advanced Biliary Cancer</brief_title>
	<detailed_description>Standard chemotherapy regimen biliary tract cancer ( BTC ) establish due difficulty associate perform clinical trial field . Gemcitabine fluoropyrimidines , include 5-fluorouracil S-1 , routinely use BTC chemotherapy . The European Society Medical Oncology ( ESMO ) National Comprehensive Cancer Network guideline publish 2009 recommend either gemcitabine-based fluoropyrimidine-based chemotherapy clinical trial first-line treatment .</detailed_description>
	<mesh_term>Biliary Tract Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Age : old 20 Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 Histologically confirm adenocarcinoma biliary tract Metastatic unresectable biliary cancer No prior chemotherapy biliary cancer A patient least one measurable primary lesion diameter confirm 10mm Spiral CT multidetector CT ( MD CT ) Adequate bone marrow , liver , renal function A patient measurable disease A patient receive previous palliative chemotherapy biliary cancer A patient receive adjuvant chemotherapy biliary cancer within 1year A patient previous active passive immunotherapy . A pregnant lactating patient</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Gemcitabine</keyword>
	<keyword>Cisplatin</keyword>
	<keyword>S-1</keyword>
	<keyword>bile duct cancer</keyword>
</DOC>